| Literature DB >> 36228298 |
Mehmet Fatih Bozkurt1, Muhammed Nasir Bhaya2, Cengiz Dibekoğlu3, Ayberk Akat4, Utku Ateş5, Oytun Erbaş6.
Abstract
PURPOSE: To evaluate the ameliorative effect of mesenchymal stem cells (MSCs) on acetic acid colitis model via Nrf2/HO-1 pathway in rats.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36228298 PMCID: PMC9553072 DOI: 10.1590/acb370704
Source DB: PubMed Journal: Acta Cir Bras ISSN: 0102-8650 Impact factor: 1.564
The results of biochemical parameters@.
| Biochemical parameters | Control group | Colitis and % 0.9 NaCl (saline) given group | Colitis and MSCgiven group |
|---|---|---|---|
| Plasma TNF-α level (pg/mL) | 16.7 ± 1.1 | 63.9 ± 2.7 | 38.3 ± 5.4 |
| Plasma PTX-3 level (ng/mL) | 0.74 ± 0.06 | 3.1 ± 0.15 | 1.6 ± 0.09 |
| Plasma MDA level (nM) | 58.5 ± 9.3 | 102.6 ± 12.6 | 98.9 ± 7.5 |
| Rectum TNF-α level (pg/mg tissue) | 61.1 ± 4.2 | 113.8 ± 9.2 | 77.4 ± 6.6 |
| Rectum Nrf-2 level (pg/mg protein) | 27.6 ± 3.5 | 10.3 ± 2.06 | 19.2 ± 1.5 |
| Rectum IL-10 level (pg/mg protein) | 1.08 ± 0.03 | 0.65 ± 0.02 | 0.84 ± 0.02 |
Data results were evaluated as mean ± standard error mean. One-way analysis of variance (ANOVA) was used;
p < 0.05 significant difference from normal groups;
p < 0.001 significant difference from normal groups;
p < 0.01 significant difference from colitis and MSCs treated groups;
p < 0.001 significant difference from colitis and MSCs treated groups; MSC: mesenchymal stem cells; TNF-α: tumor necrosis factor-α; PTX-3: pentraxin-3; MDA: malondialdehyde; IL: interleukine.
Figure 1Microphotographs of colons exposed to acetic acid and treated with stem cells. (a) Control group,(b) severe ulcerative inflammation (arrows) in a large area of the colonic mucosa in group 1. (c) Mildulcerative inflammation (arrows) in group 2. Hematoxylin and eosin (H&E), bar = actual length.
The results of histopathological parameters*.
| Groups | H&E results |
|---|---|
| Control group | 0.00 ± 0.00 |
| Colitis and % 0.9 NaCl (saline) given group | 3.40 ± 0.69 |
| Colitis and MSC given group | 2.10 ± 1.10 |
Data results were evaluated as mean ± standard error mean. One-way analysis of variance (ANOVA) was used;
p < 0.001 significant difference from normal groups;
p < 0.001 significant difference from colitis and MSCs treated groups; MSC: mesenchymal stem cells; H&E: hematoxylin and eosin.
Figure 2Immunohistochemical examination of the groups for VEGF, TNF and CD68. (a-c) VEGF: (a) Mild VEGF positivity in epithelia in the control group, (b) severe VEGF positivity in inflammatory cells (arrows) and epithelial cells (arrowheads) in group 1. (c) Decreased VEGF positivity in inflammatory cells (arrows) and epithelial cells (arrowheads) in group 2. (d) D-F: TNF-α: Mild TNF-α positivity in epithelia in the control group, (e) severe TNF-α positivity in inflammatory cells (arrows) and epithelial cells (arrowheads) in group 1. (f)Decreased TNF-α positivity in inflammatory cells (arrows) and epithelial cells (arrowheads) in group 2. (g-i) (g) CD68: few positive macrophages (red cells) in the control group, (h) many positive cells among inflammatory cells in group 1, (i) decreased CD68 positivity among inflammatory cells in group 2. ABC-peroxidase method, AEC chromogen, Gill’s hemalum. Bar = actual length.
The results of immunohistochemical evaluation*.
| Groups | TNF | VEGF | CD68 |
|---|---|---|---|
| Control group | 0.70 ± 0.48 | 0.90 ± 0.32 | 0.00 ± 0.00 |
| Colitis and % 0.9 NaCl (saline) given group | 2.40 ± 0.70 | 2.50 ± 0.71 | 1.30 ± 0.67 |
| Colitis and MSC given group | 1.10 ± 0.57 | 1.50 ± 0.85 | 0.70 ± 0.67 |
TNF: tumor necrosis factor; VEGF: vascular endothelial growth factor; MSC: mesenchymal stem cells;
data results were evaluated as mean ± standard error mean. One-way analysis of variance was used;
p < 0.001 significant difference from normal groups;
#p < 0.01 significant difference from colitis and MSCs treated groups;
p < 0.001 significant difference from colitis and MSCs treated groups.